Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma

References

• National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics – 2002. J Allergy Clin Immunol 2002;110:S141–S219
   PubMedGoogle Scholar
• Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid [Allen & Hanburys Limited UK Study Group]. Lancet 1994;344:219–24
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481–8
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997;337:1405–11
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–7
   Google Scholar
• Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730–4
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000;320:1368–73
   Google Scholar
• Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. J Am Med Assoc 2004;292:367–76
   PubMed Web of Science ®Google Scholar
• Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005:CD005533
   Google Scholar
• Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2006:CD005535
   Google Scholar
• Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. Br Med J 2005;330:117–23
   PubMed Web of Science ®Google Scholar
• Sears MR, Nelson HS, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial. Chest 2006;129:928–9
   Google Scholar
• Martinez FD. Safety of long-acting beta-agonists – an urgent need to clear the air. New Engl J Med 2005;353:2637–9
   PubMed Web of Science ®Google Scholar
• Lanes SF, Lanza LL, Wentworth 3rd CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998;158:857–61
   PubMedGoogle Scholar
• Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15 407 patients. J Clin Epidemiol 1996;49:247–50
   PubMed Web of Science ®Google Scholar
• Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998;53:7–13
   PubMed Web of Science ®Google Scholar
• Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002;57:683–6
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15–26
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904–12
   PubMed Web of Science ®Google Scholar
• Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled (betaj-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145:692–4
   PubMed Web of Science ®Google Scholar
• Lang DM. The controversy over long-acting beta agonists: examining the evidence. Cleve Clin J Med 2006;73:973–92
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Bovin JF. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149:604–10
   Google Scholar
• Rea HH, Scragg R, Jackson R. A case-control study of deaths from asthma. Thorax 1986;41:833–9
   Google Scholar
• Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001;107:937–44
   PubMed Web of Science ®Google Scholar
• Orsini L, Limpa-Amara S, Crown WH, et al. Asthma hospital-ization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004;92:523–9
   PubMed Web of Science ®Google Scholar
• Richardson D. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59
   PubMed Web of Science ®Google Scholar
• Mitchell EA, Bland JM, Thompson JM. Risk factors for readmission to hospital for asthma in childhood. Thorax 1994;49:33–6
   Google Scholar
• Clark DO, Von Korff M, Saunders K et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783–95
   PubMed Web of Science ®Google Scholar
• Senthilselvan A, Lawson JA, Rennie DC, et al. Regular use of corticosteroids and low use of short-acting ß2-agonists can reduce asthma hospitalization. Chest 2005;127:1242–51
   PubMed Web of Science ®Google Scholar
• Shireman TI, Heaton PC, Gay WE, et al. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002;36:557–64
   PubMed Web of Science ®Google Scholar
• Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006;61:306–12
   PubMed Web of Science ®Google Scholar
• Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. J Allergy Clin Immunol 2005;116:1007–13
   PubMed Web of Science ®Google Scholar
• Currie GP, Lee DK, Lipworth BJ. Long-acting beta2-agonists in asthma: not so SMART? Drug Saf 2006;29: 647–56
   Google Scholar
• Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002;89:180–9
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Chapman KR, Cartier A, et al. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001;119:714–9
   Google Scholar
• Blais R, Gregoire JP, Rouleau R, et al. Ambulatory use of inhaled ß2-agonists for the treatment of asthma in Quebec: a population-based utilization review. Chest 2001;119:1316–21
   PubMed Web of Science ®Google Scholar
• Sturdy PM, Butland BK, Anderson HR, et al. Deaths certified as asthma and use of medical services: a national case-control study. Thorax 2005;60:909–15
   PubMed Web of Science ®Google Scholar